Try our beta test site

Greatest International Antiinfective Trial With Avelox (GIANT)

This study has been completed.
Information provided by:
Bayer Identifier:
First received: July 2, 2009
Last updated: November 16, 2012
Last verified: November 2012
The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit (baseline) and at least one short-term follow-up visit (=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were documented, and a patient questionnaire was filled in.

Condition Intervention
Bronchitis, Chronic
Bronchial Diseases
Drug: Moxifloxacin (Avelox, BAY12-8039)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: GIANT - Greatest International Antiinfective Trial With Avelox®

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Evaluation of impact of AECB on the patient and the community as well as effect and safety of a treatment with moxifloxacin tablets in daily life clinical practice [ Time Frame: During documentation at baseline and at at least one short-term follow-up visit; at maximum two short-term (within ca. 14 days) and two long-term follow-up visits (after ca. 6 and 12 months). ]

Secondary Outcome Measures:
  • Course of symptom relief [ Time Frame: During documentation of up to two short-term follow-up visits (within ca. 14 days) ]
  • Speed of return to normal daily life activities [ Time Frame: During documentation of the last short-term follow-up visit (after ca. 14 days) ]
  • Adverse events collection [ Time Frame: Throughout the entire study, whenever Adverse Events occur ]
  • Evaluation of frequency of new exacerbations [ Time Frame: During documentation of up to two long-term follow-up visits (after ca. 6 and 12 months) ]
  • Progression of chronic respiratory disease [ Time Frame: During documentation of up to two long-term follow-up visits (after ca. 6 and 12 months) ]

Enrollment: 50000
Study Start Date: February 2004
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: Moxifloxacin (Avelox, BAY12-8039)
AECB patients under daily life treatment receiving moxifloxacin according to the local product information.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with a diagnosis of AECB who take moxifloxacin

Inclusion Criteria:

  • Outpatients with diagnosis of AECB and decision taken by the investigator to prescribe moxifloxacin

Exclusion Criteria:

  • Exclusion criteria must be read in conjunction with the local product information
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00932802

  Show 24 Study Locations
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Schering Pharma AG, Medical Affairs Therapeutic Area Head Identifier: NCT00932802     History of Changes
Other Study ID Numbers: 12219  AX0401  11828  12206  12214  12234  12213  12212  12216  12220  12219  12217  12225  12223  12229  12221  12218  12222  12230  12211  12227  12228  12226  12235  12233  12224  12215  12231  12232 
Study First Received: July 2, 2009
Last Updated: November 16, 2012

Keywords provided by Bayer:

Additional relevant MeSH terms:
Bronchial Diseases
Bronchitis, Chronic
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Pulmonary Disease, Chronic Obstructive
Anti-Infective Agents
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors processed this record on February 27, 2017